Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

Hsu, C\\-H.; Dziadziuszko, R.; Gomez Abreo, D. A.; Aksoy, S.; Gil Martin, M.; Roderburg, C.; Yen, C. J.; Arican, A.; Cassier, P.; Im, S\\-A.; Kim, S\\-B.; Kudo, T.; Ochsenreither, S.; Sendur, M. A. N.; Yonemori, K.; Rojas, C. I.; Liu, Q.; Keenan, T.; Healy, J.; Kwiatkowski, M.

doi:10.1016/j.annonc.2024.05.316

Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

Date

2024

Authors

dc.identifier.doi

10.1016/j.annonc.2024.05.316

dc.identifier.other

WOS:001299993900389

Publisher

ELSEVIER

DOI

10.1016/j.annonc.2024.05.316

Abstract

Gastrointestinal Cancers Congress of the European-Society-for-Medical-Oncology (ESMO), Munich, GERMANY, JUN 26-29, 2024

URI

https://openaccess.acibadem.edu.tr/handle/11443/5715

Collections

WOS

Full item page

Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By